Avadel Pharmaceuticals PLC (AVDL)vsNovartis AG ADR (NVS)
AVDL
Avadel Pharmaceuticals PLC
$21.64
0.00%
HEALTHCARE · Cap: $2.12B
NVS
Novartis AG ADR
$161.93
+0.38%
HEALTHCARE · Cap: $303.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 22983% more annual revenue ($57.36B vs $248.52M). NVS leads profitability with a 17.5% profit margin vs -0.0%. AVDL appears more attractively valued with a PEG of 0.07. NVS earns a higher WallStSmart Score of 48/100 (D+).
AVDL
Hold41
out of 100
Grade: D
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.2%
Fair Value
$70.24
Current Price
$21.64
$48.60 discount
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.93
$66.37 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Areas to Watch
0.5% revenue growth
0.0% earnings growth
Operating margin of 0.0%
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AVDL
The strongest argument for AVDL centers on PEG Ratio. PEG of 0.07 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bear Case : AVDL
The primary concerns for AVDL are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
AVDL profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
AVDL carries more volatility with a beta of 1.63 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 41/100), backed by strong 17.5% margins. AVDL offers better value entry with a 69.2% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Avadel Pharmaceuticals PLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?